Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients
NCT04529278Phase 2Unknown
- Sponsor
- Fondation Hôpital Saint-Joseph
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liraglutide in obesity and type 2 diabetes mellitus (T2DM), sponsored by Fondation Hôpital Saint-Joseph. Primary endpoint: Weight Loss at Week 26. Status: unknown.
02
Drugs
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04529278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04529278.